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Abstract
Premenstrual disorders (PMD) can affect women throughout their entire reproductive years. In
2016, an interdisciplinary expert meeting of general gynecologists, gynecological endocrin-
ologists, psychiatrists and psychologists from Switzerland was held to provide an interdiscip-
linary algorithm on PMD management taking reproductive stages into account. The Swiss PMD
algorithm differentiates between primary and secondary PMD care providers incorporating
different levels of diagnostic and treatment. Treatment options include cognitive behavioral
therapy, alternative therapy, antidepressants, ovulation suppression and diuretics. Treatment
choice depends on prevalent PMD symptoms, (reproductive) age, family planning, cardiovas-
cular risk factors, comorbidities, comedication and the woman’s preference. Regular follow-ups
are mandatory.
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Introduction
The premenstrual syndrome (PMS) and premenstrual dysphoric
disorder (PMDD) affects women during their entire reproductive
years. As symptoms vary, physicians from different disciplines
may be consulted for symptom relief, for example, general
practitioners (GP), gynecologists and psychiatrists. In order to
facilitate and improve the management of women suffering from
PMS/PMDD, an interdisciplinary expert meeting of general
gynecologists, gynecological endocrinologists, psychiatrists,
psychologists and specialists in phytotherapy from Switzerland
was held in April 2016 aiming to provide an algorithm on PMS/
PMDD management taking reproductive stages into account.
Premenstrual disorders: definition and epidemiology
The International Society for Premenstrual Disorders (ISPD) has
published and updated a consensus paper on premenstrual
disorders (PMD) [1–4]. Accordingly, a core PMD can be
distinguished from variants of PMDs (Table 1). The core PMD
can be further subdivided into (1) predominantly somatic
symptoms, (2) predominantly psychological symptoms or (3)
mixed somatic and psychological symptoms. The most frequent
psychological symptoms are mood swings, irritability, anxiety
and depression. Women with predominantly psychological symp-
toms may also fulfill the Diagnostic and Statistical
Manual (DSM)-5 criteria for PMDD [5] (Table 2).
Approximately 30–40% of women report PMS symptoms that
require treatment, while 3–8% of women during their reproduct-
ive years suffer from PMDD [6]. The duration of symptoms varies
from a few days to two weeks per menstrual cycle. Symptoms
usually worsen one week before and peak two days before
menstruation onset. A symptom-free period generally appears
before ovulation [7].
Diagnostic procedures
For optimal treatment planning, the first consultation should cover
the following aspects/questions (Table 3), followed by a basic
laboratory work-up (preferably 2nd to 5th cycle day, fasting, 8 to 9
am) (Table 4) and systematic symptom assessment. Since PMS
and PMDD symptoms are unspecific and overlap with those of
various other conditions, a valid and reliable prospective symptom
inventory is required to confirm the diagnosis [3]. In particular,
PMDD is frequently associated with psychiatric comobidities
such as depression (23%), bipolar disorder (8%) and anxiety (7%)
[8], and thus, it is important to ask the patient about any known
underlying psychiatric disorders and suicidal ideation. While
PMDD may be well differentiated from PMS by applying the
DSM-5 PMDD diagnostic criteria (Table 2), the differential
diagnostics of PMS are more of a challenge. Several tools are
available, but the Daily Record of Severity of Problems (DRSP)
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form, which has been validated as a prospectively self-adminis-
tered questionnaire, is the most commonly used at least in
English-speaking countries [9]. The DRSP consists of 17 common
PMS symptoms, including 11 symptoms from the DSM-5 PMDD
diagnostic criteria. However, the DRSP has not been validated in
German or French. There are four validated questionnaires
available in German: Revised Premenstrual Syndrome
Questionnaire (Revidierter Fragebogen zum Pra¨menstruellen
Syndrom (PMS-r)) [10], Premenstrual Symptoms Screening
Tool (Screening-Instrument fu¨r Pra¨menstruelle Symptome
(SIPS)) [11], Premenstrual Tension Syndrome Self-Rating Scale
(PMTS-SR) and Premenstrual Tension Syndrome Observer Scale
(PMTS-O) [12] and PMS Symptom Diary [13]. The PMS-r
consists of 30 items that are each rated on a on a four-point scale
from 0 (none) to 3 (severe). Two versions are available assessing
either PMS symptoms in general or current symptoms. The SIPS
consists of 14 items that are also each rated on a on a four-point
scale from 0 (none) to 3 (severe). The PMTS-SR consists of 36
items and the PMTS-O of 10 items that are either rated on a two-
point scale (yes/no) (PMTS-SR) or on a five-point scale from 0
(none) to 4 (severe) (PMTS-O), respectively. In addition, current
mood situation is assessed by a visual analog scale (scale 0–10)
consisting of four items. Regardless of the questionnaire applied,
the minimum length of recording should be two consecutive
cycles [3]. The unsolved issue of all questionnaires is that there
are no cutoff values that define PMS. In contrast, in research, the
strict PMS criteria of the National Institute of Health (NIH) need
to be fulfilled, that is an at least 30%-increase of PMS symptoms
from the follicular (day 5 to 10 of the menstrual cycle) to the
luteal phase (6 days before menses) [14]. In contrast, PMDD is
clearly defined by DSM-5 criteria [5].
Overview of treatment options
Treatment options comprise cognitive behavioral therapy (espe-
cially for PMDD), alternative treatments, psychotropic agents,
hormone-based treatments, diuretics and surgery. Importantly, in
Table 1. Classification of premenstrual disorders (PMD); adapted from Ref. (26).
Premenstrual disorder category Characteristics
Core premenstrual disorder (PMD)(PMS, PMDD) Symptoms occur in ovulatory cycles
Symptoms are not specified – they may be somatic and/or psychological
Symptoms are absent after menstruation and before ovulation
Symptoms recur in the luteal phase
Symptoms must be prospectively rated (two cycles minimum)
Symptoms must cause significant impairment (work, school, social activities, hobbies,
interpersonal activities, distress)
Variants of premenstrual disorders (PMD)
Premenstrual exacerbation
PMD due to nonovulatory ovarian activity (rare)
Progestogen-induced PMD
PMD with absent menstruation
Symptoms of an underlying psychological, somatic or medical disorder significantly worsen
premenstrually
Symptoms result from ovarian activity other than those of ovulation
Symptoms result from exogenous progestogen administration
Symptoms arise from continued ovarian activity even though menstruation has been
suppressed
Table 2. DSM-5 Criteria of premenstrual dysphoric disorder (PMDD)
(2).
A. In the majority of menstrual cycles, at least 5 symptoms must be
present in the final week before the onset of menses, start to improve
within a few days after the onset of menses, and become minimal or
absent in the week postmenses.
B. 1 symptom must be present:
 Marked affective lability (e.g. mood swings, sudden sadness,
increased sensitivity to rejection)
 Marked anger or irritability or increased interpersonal conflicts
 Marked sense of hopelessness, depressed mood, self-critical
thoughts
 Marked tension, anxiety, feeling on edge
C. 1 symptom must be aditionally present to reach a total of 5
symptoms when combined with symptoms from criterion B above:
 Difficulty concentrating
 Change in appetite, food cravings, overeating
 Diminished interest in usual activities
 Easy fatigability, decreased energy
 Feeling overwhelmed or out of control
 Breast tenderness, bloating, weight gain or joint/muscles aches
 Sleeping too much or not sleeping enough
D. The symptoms are associated with clinically significant distress or
interference with work, school, usual social activities, or relation-
ships with others.
E. The disturbance is not merely an exacerbation of the symptoms of
another disorder or personality disorder (although it may co-occur).
F. Criterion A should be confirmed by prospective daily ratings during
at least 2 symptomatic cycles.
G. The symptoms are not attributable to the physiological effects of a
substance or another medical condition.
Table 3. Basic information necessary for shared decision making on
PMD treatment; modified according to Ref. (19,27,28).
 Menstrual history/reproductive stage: frequency, duration, heaviness,
pain, regularity, amenorrhea, last menstrual period, pregnancy
 PMD history: age at onset, character, timing, severity, absence of
presence after menstruation, symptom-free interval during follicular
phase
 Impairment: effect on work, school, social activities, family etc. (at
least 3-5 days); level of distress
 Underlying medical problem (psychological, physical, medical) that
worsen before menstruation onset
 Suicidal ideation
 Tolerance of previous or ongoing hormonal treatment
 Family planning and willingness to use barrier methods of contra-
ception during treatment
 Attitude towards (unlicensed) PMD treatment options
 History of PMD treatment: efficacy, side effects
 Adherence to medication
Table 4. Basic laboratory work-up (serum).
Endocrine disorder/status Serum marker
Reproductive stage Follicle stimulating hormone (FSH),
estradiol (E2)
Thyroid disorder Thyroid stimulating hormone (TSH)
Hyperprolactinemia Prolactin
Cushing syndrome/M. Addison Cortisol
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Switzerland, except for chasteberry (Vitex agnus-castus L.) and
progesterone none of the following therapeutic options is
approved for PMD treatment.
Alternative treatments
Alternative therapies include diet, exercise, micronutrients (cal-
cium, pyridoxine, magnesium, vitamin E, myo-inositol), herbal
pharmacological treatments (chasteberry (Vitex agnus-castus L.),
St John’s wort (Hypericum perforatum L.), evening primrose oil
(Oenothera biennis L.), saffron (Crocus sativus L.), Gingko
biloba L., and non-pharmacological treatments such as cognitive-
behaviour therapy and acupuncture. Importantly, herbal treat-
ments may be approved as food supplements or drugs registered
by Swissmedic in which case they respond to efficacy, safety and
production control criteria. The strongest evidence for efficacy of
alternative treatments for PMD exists for calcium, chasteberry
(Vitex agnus-castus L.) and cognitive-behaviour therapy (Table 5)
[3,15]. A systematic review found chasteberry extracts to be
superior to placebo, pyridoxine and magnesium oxide in women
with PMS [16]. In women with PMDD, one study reported
chasteberry to be equivalent to fluoxetine [17], while in the other,
fluoxetine outperformed chasteberry [18]. Vitex agnus-castus was
effective in reducing both, somatic and mental symptoms [16].
The overall response of PMD patients to Vitex agnus-castus L.
ranged between 52–81% [16,19]. A treatment period of at least 3
month is recommended [20,21]. However, it should be kept in
mind, that chasteberry is a dopaminergic agonist [21] and might
thus interfere with antipsychotics (no studies yet).
Psychotropic agents
Psychotropic agents comprise antidepressants and anxiolytics
(Table 6) [1,2,3,15,22]. Antidepressants can be applied continu-
ously or during the luteal phase only (start: 14 days before the
expected onset of menstrual bleeding; stop: onset of menstrual
bleeding or a few days later). The overall response of PMD
patients to selective serotonin reuptake inhibitors (SSRI) ranges
between 50–90% [23,24]. The beneficial effect can be expected
within 48 h of treatment initiation. While continuous and inter-
mittent SSRI treatments are equally effective at reducing
irritability and mood swings, continuous SSRI treatment is
more effective in reducing depressed mood and somatic symp-
toms [25,26]. If there is insufficient response in the first treatment
cycle, the dose might be increased in the next cycle or the type of
SSRI may be changed. Side effects, such as nausea, insomnia,
headache, fatigue, diarrhea and dizziness, are common at SSRI
initiation (incidence 15%) but usually abate within a few days of
treatment. In contrast, sexual dysfunction such as decreased libido
or delayed orgasm may be persistent (incidence 9–30%) but
recovers rapidly after SSRI discontinuation. So far, suicide
attempts have not been reported in women with PMD using
SSRI or SNRI, respectively [27]. Although discontinuation
symptoms are rare SSRI dose may be tapered, especially when
given on a continuous basis [27]. After discontinuing treatment,
about 50% of patients experience a relapse within 6–8 months.
But even in women on medication relapse may occur [28].
Combining SSRI with other medications (e.g. association of
multiple antidepressants) has not been systematically studied for
PMD treatment.
Similar to SSRI, selective serotonin norepinephrine reuptake
inhibitors (SNRI), tricyclic antidepressants and anxiolytics have
been shown to improve PMD. However, the body of evidence is
much smaller [15].
In women presenting with variant PMD, such as premenstrual
exacerbation, of an underlying psychiatric disorder antidepressant
therapy should be established in close collaboration with a
psychiatrist as in some patients with, for example, prepsychotic
disorder, SSRI may aggravate the underlying psychiatric condi-
tion. Furthermore, when treating fertile women for core PMD,
choosing a SSRI compatible with pregnancy (e.g. sertraline,
citalopram) is recommended.
Suppression of ovulation
Ovulation can be suppressed by using combined oral contracep-
tives (COC), gonadotropin-releasing hormone agonists (GnRH-
A), estrogens and danazol (not available anymore in Switzerland)
(Table 7). While early studies showed a negative impact of COC
on affective symptoms in women suffering from PMD, there are
others, especially those containing the progestogen drospirenone
and/or with shortened pill-free interval that demonstrated a
benefit for affective and somatic symptoms, respectively
[3,15,29]. However, as COC increase the risk of venous
thromboembolism, adequate counseling is mandatory [30].
GnRH-A downregulate the hypothalamus–pituitary–ovary
axis, thereby inducing a pseudo-menopausal state. The response
rate in women with PMD has been reported to be 60–75% for
both, physical and behavioral symptoms [31]. GnRH-A are
Table 6. Psychotropic treatment PMD options; modified according to
Ref. (23).
Antidepressant Dosage
Selective serotonin reuptake inhibitors (SSRI)
 Sertraline 50–150 mg/day; continuous or luteal phase
 Fluoxetine 10–20 mg/day; continuous or luteal phase
 Escitalopram 10–20 mg/day; continuous or luteal phase
 Paroxetine 12.5–25 mg/day; continuous or luteal phase
 Citalopram 10–30 mg/day; continuous or luteal phase
Selective serotonin norepinephrine reuptake inhibitors (SNRI)
 Venlafaxine 50–200 mg/day; continuous or luteal phase
 Duloxetine 60 mg/day; continuous
Tricyclic antidepressants




0.75 mg/day; luteal phase
 Buspirone 10–40 mg/day; luteal phase
Table 5. Alternative treatments (selection); modified according to Ref.
(23).
Micronutrient Dosage
Calcium 1200 mg/day; continuous
Vitamin E 150–600 IU/day; continuous
Vitamin B6 (pyridoxine) 50–100 mg/day; continuous
Magnesium 200–500 mg/day; continuous
Myo-inositol 12 g/day powder; continuous
Herbal therapy Dosage
Vitex agnuscastus L., fructus
(chasteberry)
20 mg/day*; continuous
Hypericum perforatum L., herba
(St John’s wort)
900 mg/day*; continuous
Oenothera biennis L., oleum
(evening primrose oil)
1–6 g/day; continuous
Crocus sativus L. (Saffron) 30 mg/day*; continuous
Gingko biloba L., folium 120–160 mg/day*; luteal phase
*dry extract.
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usually accompanied by ‘‘add-back’’ menopausal hormone ther-
apy (MHT; estrogens combined with progestogens, tibolone) to
avoid estrogen deficiency sequelae such as hot flushes and
osteoporosis [3,6]. However, long-term safety data are not
available yet. Thus, bone densitometry scans are recommended
if GnRH-A (±MHT) are applied for more than six months and at
least at two-year intervals thereafter or at individual intervals,
respectively (cave: might not covered by health insurance).
Treatment should be stopped if bone density declines significantly
in scans performed one year apart [27].
Transdermal and injectable, but not oral estrogens [32–34]
suppress ovulation and significantly improve PMD symptoms
compared to placebo. For endometrial protection, a progestogen
needs to be combined, for example, dydrogesterone (no
centralnervous effect) or a levonorgestrel-containing intrauterine
device (Mirena). The latter has some systemic absorption with
highest levels in the first 3–4 months, which may induce
symptoms such as depression, tiredness and bloating in about
10% of women with progestogen intolerance [35]. Usually, these
symptoms disappear thereafter.
Obviously, surgery with bilateral oophorectomy and hysterec-
tomy remains the last-resort treatment for PMD. The beneficial
effect on both mood and physical PMD symptoms has been
shown, but only as long as add-back MHT with estrogens
(unopposed) is administered. Prior to surgery, the potential effect
of oophorectomy should be tested by using GnRH-A [3].
Progestogens
Neither progestins nor progesterone have been proven to be
effective in women suffering from PMD and are therefore not
generally recommended [1,2,22,27,36]. However, the most recent
Cochrane review stated that the (heterogeneous) trials included
did not show that progesterone was not an effective treatment for
PMS [37].
Diuretics
Spironolactone, an aldosterone receptor antagonist, at 100 mg/day
during the luteal phase has been shown to reduce both physical
and affective symptoms [38,39]. As spironolactone is a potas-
sium-sparing diuretic, patients should peridiodically be monitored
for hyperkalemia [15].
Swiss algorithm for PMD management
The Swiss algorithm for PMD management seeks to incorporate
the structural level of medical care (primary/secondary care) as
well as varying content levels (diagnostics, treatment) depending
on the reproductive stage of a woman (reproductive phase,
menopausal transition (MT)) [40].
On the hierarchical level (Figure 1), GPs and general
gynecologists are responsible for primary PMD care, while
gynecological endocrinologists (lead clinician), psychiatrists and
psychologists are providers of secondary PMD care. Together
with the patient, they form a therapeutic triangle that may be
supplemented by for example approved alternative medicine
specialists and surgeons if indicated. Primary clinical diagnostics
(personal history, prospective symptom assessment) should be
performed by the primary PMD care provider. The interdiscip-
linary expert panel recommends to use the PMS-r either daily or
at least twice per menstrual cycle (e.g. during follicular phase
(cycle day 5–7) and luteal phase (either 14 days later or 6 days
prior to the next menstruation)) during two consecutive cycles.
For French-speaking patients, the Calendar of Premenstrual
Experiences (COPE) is currently used. Its translation in French
has however never been validated.
If first- and second-line treatment (Figures 2 and 3) is not
successful, the patient should be refered to a secondary PMD care
provider, preferably to a gynecological endocrinologist. A
psychiatrist is the preferred secondary PMD care provider if a
woman presents with variant PMD with psychiatric co-morbidity.
Clinical diagnostics will then be completed by a serum laboratory
work-up and eventually by another prospective symptom assess-
ment during two consecutive cycles.
The proposed treatment algorithm distinguishes between
women during their reproductive years and women during the
MT [40]. Each treatment trial should be documented in the same
way as during the diagnostic cycles.
Psychoeducation should be the basis for all following
treatment options. For treatment-naı¨ve women in their reproduct-
ive years (Figure 2), first-line treatment comprises alternative
therapy (at least 2–3 months). In nonresponders or pretreated
women, second-line treatment comprises either a 2-month course
of COC (if contraception is needed and VTE risks are absent) or
antidepressants (SSRI, SNRI) (if no contraception is needed or
VTE risks are present) at different dosages and regimens. Patients
who start on SSRIs should be offered a follow-up appointment
(face to face or phone) 1 week after treatment start in order to
assess for increased anxiety [4]. In women seeking to become
pregnant, citalopram and sertraline are the preferred SSRI.
Tricyclic antidepressants and anxiolytics should only be pre-
scribed by psychiatrists and in women with severe PMDD.
In nonresponders or women with side effects, third-line
treatment can be either spironolactone or ovulation suppression
Table 7. Supression of ovulation for PMD treatment, modified according to Ref. (23,26).
Suppression of ovulation Dosage; regimen
Combined oral contraceptives (COC) (selection)  20 mcg ethinylestradiol + 3 mg drospirenone; monophasic 24/4*
 20 mcg ethinylestradiol + 90 mcg levonorgestrel; monophasic continuously
 35 mcg ethinylestradiol + 0.5/1/0.5 mg norethindrone; triphasic 21/7
 30 mcg ethinylestradiol + 150 mcg desogestrel; monophasic 21/7
 30 mcg ethinylestradiol + 150 mcg levonorgestrel; monophasic 21/7
 30/40/30 mcg ethinylestradiol + 50/75/125 mcg levonorgestrel; triphasic 21/7
 30 mcg ethinylestradiol + 2 mg chlormadinone acetate; monophasic 21/7
Gonadotropin-releasing hormone
agonists (GnRH-A)
 Leuprolid 3.75 mg i.m./month
 Goserelin 3.6 mg s.c./month or 10.8 mg s.c./3 months
Buserelin 3 100 mcg/day nasal spray
Transdermal estrogens  Estradiol 2–4 100 mcg patches/week (combined with a progestogen
for endometrial protection)
mcg: microgram; s.c: subcutaneous; i.m: intramuscular.
*Approved by the FDA for treatment of PMDD in women who desire contraception.








side effects after 2 cycles
Non-responder/side effects after 2 cycles
Non-responder / side effects after 2 cycles
Non-responder / side effects after 2 cycles
Antidepressants
Patients (women in their reproductive years)  presenting with premenstrual symptoms
Clinical diagnostics: personal history, prospective symptom assessment (I°+ II° care), laboratory work-up (II° care)
PMD variant: premenstrual exacerbation 
of a co-morbidity
Treatment should aim to treat underlying 
medical, physical, or psychiatric condition or 
suppress ovulation (or both)
Alternative progestogen treatment
Core PMD: PMS or PMDD
Spironolactone (luteal)**
Ovulation suppression: GnRH-A + add-back MHT
Ovulation suppression: surgery (HE+BSO)
SSRI / SNRI (luteal or continuous)*
Change SSRI / SNRI dosage (luteal or continuous) 
Switch SSRI / SNRI type, dosage or regime (continuous use if luteal before) 







Ovulation suppression: transdermal estradiol 
(+ oral dydrogesterone 10 mg 17th – 28th CD or Mirena®)





Non-responder after 2–3 cycles
need for contraception + VTE risks absent NO need for contraception or VTE risks present
no
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* Patients who start SSRIs should be offered a follow-up 
appointment (face-to-face or phone) 1 week after treatment 
has commenced in order to assess for increased anxiety
** Need to counselled to use barrier methods for contraception 
and to have serum potassium checked frome time to time
Non-responder / side effects after 1 cycle
Non-responder / side effects after 1 cycle
Non-responder / side effects after 1 cycle
Non-responder / side effects after 1 cycle























Figure 1. Premenstrual disorder (PMD) health care model.
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by transdermal estrogens combined with a progestogen for
endometrial protection. Women choosing spironolactone need to
be counseled to use barrier methods for contraception and to have
serum potassium checked from time to time.
Women who do not respond to any third-line treatment option
may be offered ovulation suppression by GnRH-A combined with
add-back MHT (fourth-line treatment). In responders, bone
densitometry should be evaluated after six months and at least
at two-year interval thereafter or at individual intervals, respect-
ively (might not covered by insurance!). Surgery with hysterec-
tomy and bilateral oophorectomy is the last-resort treatment und
not necessary in most cases.
Women suffering from core PMD during their reproductive
years should be informed about their increased risk of depression
during pregnancy, postpartum and the perimenopause in order to
provide easy and fast access to interdisciplinary medical care
during hormone-sensitive life stages.
Women during the MT may face a new onset or worsening of
premenstrual symptoms. Early MT is characterized by a variation
of the menstrual cycle length that exceeds 7 days, more
consistently elevated FSH serum levels and a decreased ovarian
reserve. Late MT is characterized by irregular and scarce
menstrual cycles, more likely low estrogen serum levels and an
increased prevalence of common menopausal symptoms [40,41].
Similar to women suffering from PMD during their repro-
ductive life span, treatment-naı¨ve women during the MT
(Figure 3) may try alternative therapy as first-line treatment
(2–3 months). In nonresponders or pretreated women, second-line
treatment comprises either a 2-month course of E2-containing
COC (if contraception is needed and VTE risks are absent), oral
progesterone (early MT, if no contraception is needed or VTE
risks are present) or ovulation suppression by transdermal
estrogens combined with a progestogen for endometrial protection
(late MT, if no contraception is needed or VTE risks are present).
In nonresponders or women with side effects, further treatment
options comprise antidepressants, spironolactone (third-line treat-
ment), GnRH-A combined with add-back MHT (fourth-line
treatment) and surgery with hysterectomy and bilateral oophor-
ectomy (last resort treatment). In conclusion, the Swiss algorithm
for PMD management is a tool to triage PMD care with regards to
reproductive life stage in an interdisciplinary context. Medical
care is structured on five treatment levels.
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